Streetwise Reports' Article Archives — May 2019 back to current month (18)
The interim study results for an in-progress trial evaluating this asset are discussed in a ROTH Capital Partners report.
The Canadian company's approach to this indication is now twofold.
The transaction details and the drug platform's potential are addressed in an H.C. Wainwright & Co. report.
The biopharma's two assets are discussed and Q1/19 financial results are provided in a BTIG research report.
The partnership news and upcoming data readouts are reviewed in an H.C. Wainwright & Co. report.
With study results from this company due out shortly, an analysis of the possible outcomes was provided in a ROTH Capital Partners report.
Cancer Fighter Sesen Bio Leaps 13% on FDA Decision (05/21/2019)
Shares of this biotech stock were up significantly at the close of trading on Tuesday, May 21, attributed to the announcement of some good news from the FDA.
The company continues to make preparations while it awaits receipt of a sales license.
Harrow Comes Out of Allergan Lawsuit Unscathed (05/17/2019)
Sector expert Daniel Carlson offers his take on the recent jury decision, calling it "very positive."
Why Did ImmunoGen Plummet 32%? (05/16/2019)
This biotechnology company, which focuses on the treatment of cancer, received some feedback from the FDA that upset investors on Wednesday.
A review of this Colorado company's first numbers of the year was provided in a Ladenburg Thalmann report.
An update on this biopharma's two lead drug candidate programs was provided in an H.C. Wainwright report.
The results compare favorably to those of the historical control group.
The first patient has been treated in the second cohort of a Phase 2 study of a gene therapy targeting Parkinson's disease, explained an H.C. Wainwright & Co. report.
The expected data and their implications were addressed in a ROTH Capital Partners report.
This small-cap nutrascience stock hit a new 52-week high on May 6th, extending a run that has the stock up 147% over a five-day period.
A study update and the next steps to advance the therapeutic were covered in a ROTH Capital Partners report.
Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report.
|"Experiments showed that PMN's PMN310 has a unique binding profile."|